A Phase 1/2 interventional study of Axolotl Ambient and "Drug/Placebo: 0.9% Normal Saline" in Ankle Osteoarthritis, sponsored by Axolotl Biologix. Terminated at 3 sites in United States. Open to participants aged 18 Years to 80 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-08-07.
Sponsored by Axolotl Biologix · Phase 1/2, Interventional, and Treatment
A Double-blind, Multi-Center, Prospective, Randomized Placebo-controlled Pilot Study Evaluating Intra-articular Injection of Axolotl Ambient Compared to Saline in Subjects with Ankle Osteoarthritis. The goal of this pilot study and subsequent pivotal trial is to evaluate the safety and effectiveness of Axolotl Ambient intra-articular injection for ameliorating the pain and dysfunction associated with ankle OA.
This pilot study is a double-blind multi-center, prospective, randomized, placebo-controlled trial. Upon randomization, patients will receive 1 intraarticular injection of the investigational product or control fluid. Follow-up will be conducted at 4 weeks, 3 and 6 months, with 6 months serving as the primary endpoint. The primary outcomes will consist of patient reported outcomes of pain and functional assessment by the physician, specific to the foot and ankle. Subjects will be monitored for an additional 6 months to establish safety over a 1-year follow-up and evaluate the durability of benefit.
Exclusion Criteria:
Single dose, 2.0 mL of 0.9% normal saline, administered via intra-articular injection administered to the affected tibiotalar joint.
Drug: "Drug/Placebo: 0.9% Normal Saline"
Biological/Vaccine: Axolotl Ambient Axolotl Ambient is an allogeneic amniotic intraarticular injection therapy consisting of a growth factor and cytokine-rich fluid derived from human amnion cells. Other Names: • CA20
Biological: Axolotl Ambient
Axolotl Ambient is an allogeneic amniotic intra-articular injection therapy consisting of a growth factor and cytokine-rich fluid derived from human amnion cells.
Also known as: CA20
"Drug/Placebo: 0.9% Normal Saline"
Change From Baseline in Ankle Osteoarthritis Scale (AOS; 48 hr Recall) Pain Subscale
The Ankle Osteoarthritis Scale (AOS) pain subscale goes from 0 (No pain) -100 (The worst imaginable).
Time frame: 4-weeks, 3-months, and 6-months
Change From Baseline for Ankle Osteoarthritis Scale (AOS; 48 hr Recall) Function Subscale
The Ankle Osteoarthritis Scale (AOS) functions subscale goes from 0 (No difficulty) -100 (So difficult, unable).
Time frame: 4-week, 3 Months, 6-months
Change From Baseline for Foot and Ankle Outcome Score (FAOS) for Pain Subscale
A score of 100 represents no pain. A score of 0 constant pain.
Time frame: 4-weeks, 3-months, 6-months
Change From Baseline for Foot and Ankle Outcome Score (FAOS) for Function Subscale
100 represents perfect health and 0 represents extreme problems and complete functional limitation. .
Time frame: 4-weeks, 3-months, 6-months
Proportion of Patients Achieving Composite Clinical Success (CCS).
CCS defined as a patient meeting all of the three following criteria: 1. Improvement in AOS (Pain and Function) or FAOS scores (Pain and ADL) of at least 20% from baseline 2. No surgical intervention or prescription pain medications for ankle OA 3. No treatment or procedure-related serious adverse events
Time frame: 4-weeks, 3-months, 6-months
Incidence of Adverse Events
Proportion of subjects experiencing at least (1) adverse events.
Time frame: Post-procedure follow-up assessments: 4 weeks (+/-7days), 3 Months (+/- 14 days), 6 Months (+/- 30 days), 12 Months (+/- 60 days), and unscheduled visits (up to 19 months)
FAOS Subscales Quality of Life (QoL)
0 (most severe problems) to 100 (no problems/best possible qualify of life)
Time frame: 4-week, 3-month, 6-month
Visual Analog Scale (VAS) for Ankle Pain (Average During Last 48 Hours)
100 millimeter scale 0mm - No Pain and 100mm - Worst Imaginable Pain
Time frame: 4 weeks, 3-months, 6-months
VAS Ankle Pain (Worst During Last 48 Hours)
100 millimeter scale 0mm - No Pain and 100mm - Worst Imaginable Pain
Time frame: 4-weeks, 3-months, 6-months
EuroQOL-5 Dimension-5 Level (EQ-5D-5L) Quality of Life Scale
0 to 100 scale - 0 the worst health you can imagine to 100 the best health you can imagine.
Time frame: 4-weeks, 3-months, 6-months
Working Status
Not working, unrelated to ankle Not working, related to ankle Working with major limitations related to ankle Working without limitations related to ankle
Time frame: Baseline, 4-weeks, 3-months, 6-months
K-L Grade From Weightbearing X-ray at Baseline and 6 Months
Grade 2 Definite osteophytes with mild to moderate joint space narrowing; early radiographic OA Grade 3a Significant osteophytes and joint space narrowing, but greater than 50% of the joint space remains preserved Grade 3b Severe joint space narrowing with less than 50% remaining joint space, approaching end-stage disease but not completely bone-on-bone Grade 4 Near complete or complete loss of joint space with substantial deformity (end-stage OA)
Time frame: Baseline, 6-months
| Milestone | Control Group | Investigational Group |
|---|---|---|
| Started | 6 | 6 |
| Completed | 2 | 2 |
| Not completed | 4 | 4 |
The Ankle Osteoarthritis Scale (AOS) pain subscale goes from 0 (No pain) -100 (The worst imaginable).
| score on a scale | Control Group | Investigational Group |
|---|---|---|
| 4-weeks | -7.0 ± 24.08 | -2.2 ± 23.32 |
| 3-months | -11.7 ± 31.97 | 19.3 ± 32.75 |
| 6-months | -4.5 ± 12.47 | 6.3 ± 16.26 |
The Ankle Osteoarthritis Scale (AOS) functions subscale goes from 0 (No difficulty) -100 (So difficult, unable).
| score on a scale | Control Group | Investigational Group |
|---|---|---|
| 4-weeks | -13.3 ± 23.55 | -0.6 ± 23.51 |
| 3-months | -14.2 ± 19.05 | 12.3 ± 24.03 |
| 6-months | -7.3 ± 7.74 | 8.7 ± 21.08 |
A score of 100 represents no pain. A score of 0 constant pain.
| score on a scale | Control Group | Investigational Group |
|---|---|---|
| 4-weeks | 10.0 ± 15.97 | 5.8 ± 22.33 |
| 3-months | 16.5 ± 14.60 | -13.0 ± 20.42 |
| 6-months | 8.8 ± 7.79 | -6.3 ± 12.66 |
100 represents perfect health and 0 represents extreme problems and complete functional limitation. .
| score on a scale | Control Group | Investigational Group |
|---|---|---|
| 4-weeks | 5.0 ± 8.69 | 2.8 ± 11.82 |
| 3-months | 8.5 ± 7.92 | -6.7 ± 10.97 |
| 6-months | 4.7 ± 2.50 | -3.3 ± 7.37 |
CCS defined as a patient meeting all of the three following criteria: 1. Improvement in AOS (Pain and Function) or FAOS scores (Pain and ADL) of at least 20% from baseline 2. No surgical intervention or prescription pain medications for ankle OA 3. No treatment or procedure-related serious adverse events
| Participants | Control Group | Investigational Group |
|---|---|---|
| 4-weeks | 3 | 1 |
| 3-months | 3 | 1 |
| 6-months | 2 | 0 |
Proportion of subjects experiencing at least (1) adverse events.
| Participants | Control Group | Investigational Group |
|---|---|---|
| Incidence of Adverse Events | 5 | 2 |
0 (most severe problems) to 100 (no problems/best possible qualify of life)
| score on a scale | Control Group | Investigational Group |
|---|---|---|
| 4-weeks | 12.5 ± 17.27 | 11.4 ± 38.62 |
| 3-months | 14.5 ± 20.39 | 0.0 ± 13.00 |
| 6-months | 9.0 ± 18.60 | 2.0 ± 3.46 |
100 millimeter scale 0mm - No Pain and 100mm - Worst Imaginable Pain
| score on a scale | Control Group | Investigational Group |
|---|---|---|
| 4-weeks | 3.0 ± 43.69 | -0.6 ± 33.47 |
| 3-months | -12.2 ± 40.91 | 26.0 ± 29.00 |
| 6-months | -15.3 ± 14.29 | 8.7 ± 15.82 |
100 millimeter scale 0mm - No Pain and 100mm - Worst Imaginable Pain
| score on a scale | Control Group | Investigational Group |
|---|---|---|
| 4-weeks | -4.2 ± 32.85 | 2.2 ± 38.80 |
| 3-months | -11.2 ± 39.21 | 35.3 ± 35.92 |
| 6-months | -13.7 ± 16.77 | 5.0 ± 10.00 |
0 to 100 scale - 0 the worst health you can imagine to 100 the best health you can imagine.
| score on a scale | Control Group | Investigational Group |
|---|---|---|
| 4-weeks | 8.3 ± 13.94 | -0.4 ± 21.87 |
| 3-months | -0.2 ± 20.74 | -20.0 ± 21.79 |
| 6-months | -5.7 ± 29.14 | -6.7 ± 7.64 |
Not working, unrelated to ankle Not working, related to ankle Working with major limitations related to ankle Working without limitations related to ankle
| Participants | Control Group | Investigational Group |
|---|---|---|
| Baseline — Not working, unrelated to ankle | 2 | 1 |
| Baseline — Not working, related to ankle | 1 | 0 |
| Baseline — Working with major limitations related to ankle | 0 | 1 |
| Baseline — Working without limitations related to ankle | 3 | 4 |
| 4-weeks — Not working, unrelated to ankle | 1 | 1 |
| 4-weeks — Not working, related to ankle | 0 | 0 |
| 4-weeks — Working with major limitations related to ankle | 2 | 0 |
| 4-weeks — Working without limitations related to ankle | 3 | 4 |
| 3months — Not working, unrelated to ankle | 1 | 0 |
| 3months — Not working, related to ankle | 0 | 0 |
| 3months — Working with major limitations related to ankle | 2 | 1 |
| 3months — Working without limitations related to ankle | 3 | 2 |
| 6months — Not working, unrelated to ankle | 2 | 0 |
| 6months — Not working, related to ankle | 0 | 0 |
| 6months — Working with major limitations related to ankle | 2 | 1 |
| 6months — Working without limitations related to ankle | 2 | 2 |
Grade 2 Definite osteophytes with mild to moderate joint space narrowing; early radiographic OA Grade 3a Significant osteophytes and joint space narrowing, but greater than 50% of the joint space remains preserved Grade 3b Severe joint space narrowing with less than 50% remaining joint space, approaching end-stage disease but not completely bone-on-bone Grade 4 Near complete or complete loss of joint space with substantial deformity (end-stage OA)
| Participants | Control Group | Investigational Group |
|---|---|---|
| baseline Day 0 — Grade 2 Definite osteophytes with mild to moderate joint space narrowing; early radiographic OA | 4 | 2 |
| baseline Day 0 — Grade 3a | 1 | 3 |
| baseline Day 0 — Grade 3b | 1 | 0 |
| baseline Day 0 — Grade 4 | 0 | 0 |
| 6 Month — Grade 2 Definite osteophytes with mild to moderate joint space narrowing; early radiographic OA | 3 | 0 |
| 6 Month — Grade 3a | 1 | 1 |
| 6 Month — Grade 3b | 0 | 0 |
| 6 Month — Grade 4 | 0 | 0 |
Collected over 19 months. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Control Group | 0/6 (0%) | 0/6 (0%) | 5/6 (83.3%) |
| Investigational Group | 0/6 (0%) | 0/6 (0%) | 2/6 (33.3%) |
| Event | Control Group | Investigational Group |
|---|---|---|
| Back PainMusculoskeletal and connective tissue disorders | 3/6 | 0/6 |
| Foot and Ankle PainMusculoskeletal and connective tissue disorders | 3/6 | 0/6 |
| Hip PainMusculoskeletal and connective tissue disorders | 2/6 | 0/6 |
| Back InjuryMusculoskeletal and connective tissue disorders | 0/6 | 1/6 |
| Left Hip OsteoarthritisMusculoskeletal and connective tissue disorders | 0/6 | 1/6 |
| Muscle SpasmsMusculoskeletal and connective tissue disorders | 1/6 | 0/6 |
| Knee PainMusculoskeletal and connective tissue disorders | 1/6 | 0/6 |
| Foot NumbnessMusculoskeletal and connective tissue disorders | 1/6 | 0/6 |
| Wrist PainMusculoskeletal and connective tissue disorders | 1/6 | 0/6 |
| BronchitisRespiratory, thoracic and mediastinal disorders | 1/6 | 0/6 |
| Age, Categorical(Participants) | Control Group | Investigational Group | Total |
|---|---|---|---|
| <=18 years | 0 | 0 | 0 |
| Between 18 and 65 years | 6 | 6 | 12 |
| >=65 years | 0 | 0 | 0 |
| Sex/Gender, Customized(Participants) | Control Group | Investigational Group | Total |
|---|---|---|---|
| Male or Female | 6 | 6 | 12 |
| Race and Ethnicity Not Collected(Participants) | Control Group | Investigational Group | Total |
|---|---|---|---|
| Count of participants | — | — | 0 |
| Region of Enrollment(participants) | Control Group | Investigational Group | Total |
|---|---|---|---|
| United States | 6 | 6 | 12 |
Documents are hosted by the registry — open the source record to download them.
Plan to share: No
This study is terminated, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Axolotl Biologix